Oncology Experts

Mark R. Gilbert

Senior Investigator
Neuro-Oncology Branch, CCR
National Cancer Institute
United States of America


Dr. Gilbert is a senior investigator and chief of the Neuro-Oncology Branch (NOB), which is a collaboration between NCI and the National Institute of Neurological Disorders and Stroke (NINDS). HIs vision is to build a highly collaborative, robust translational research program centered on finding treatments for brain and other central nervous system tumors where basic research observations will be rapidly translated into pre-clinical testing and then hypothesis-based clinical research trials, including important correlative studies. Dr. Gilbert received his medical doctorate (M.D.) degree in medicine from Johns Hopkins University (JHU) in 1982 (Alpha Omega Alpha). At JHU, he completed residencies in internal medicine (1982-1985) and neurology (1984-1988) and fellowship training (Keck Foundation Fellowship) in both neurology and neuro-oncology. In 2000, after serving on the faculties of the University of Pittsburgh and Emory University in Atlanta, Georgia, Dr. Gilbert joined the University of Texas MD Anderson Cancer Center as Deputy Chair of the Department of Neuro-oncology. In 2005, he was appointed as Director of the Brain Tumor Trials Collaborative, a multi-center clinical trials consortium. In 2009, Dr. Gilbert received the Blanche Bender Endowed Professorship in Cancer Research. Recently, he was named the Co-Chair of the Brain Tumor Committee in the Radiation Therapy Oncology Group (RTOG). Dr. Gilbert is also the founder and former leader of the Collaborative Ependymoma Research Network (CERN), a consortium studying ependymoma, a rare central nervous system cancer, by supporting basic research, clinical trials, patient outcomes research and educational efforts in North America and Europe.

Research Interest

1) Neuro-oncology, 2) Neurology, 3) Primary brain tumors, 4) Development of new treatment strategies, 5) Clinical Research, 6) Neuroscience.


  • Cilengiyide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

  • A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

  • A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Global Experts from United States of America

Global Experts in Subject